Prostatic specific antigen and the prediction of prognosis in metastatic prostatic cancer.
Serum prostate-specific antigen (PSA) levels were studied in the EORTC trial of zoladex plus flutamide versus orchidectomy in metastatic prostatic cancer. Forty-four of 60 patients had a decrease of PSA to less than or equal to 10 ng/ml at 3 to 6 months after treatment. The combination of a PSA less than 10 ng/ml after 3 to 6 months treatment and less than 15 spots on the bone scintigram at entry gave the highest probability of not having progressed by 24 months. A rising PSA anticipated bone progression by 6 to 12 months in 13 of 28 patients (46%). The PSA at entry to the trial was related to survival; a discriminant of 300 ng/ml distinguished a poor and better risk group. The lowest level of PSA reached during the first 6 months of treatment was also a univariate survival factor.
Unit for Cancer Research, University of Leeds, UK.
E H
EH
Cooper
T G
TG
Armitage
M R
MR
Robinson
D W
DW
Newling
B R
BR
Richards
P H
PH
Smith
L
L
Denis
R
R
Sylvester
D000951:Antigens, Neoplasm / Q000097:blood*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood*; D001859:Bone Neoplasms / Q000000981:diagnostic imaging* / Q000556:secondary; D002064:Buserelin / Q000008:administration & dosage / Q000031:analogs & derivatives; D005485:Flutamide / Q000008:administration & dosage; D017273:Goserelin; D006801:Humans; D008297:Male; D009919:Orchiectomy; D011237:Predictive Value of Tests; D011379:Prognosis; D017430:Prostate-Specific Antigen; D011471:Prostatic Neoplasms / Q000276:immunology* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D011877:Radionuclide Imaging; D015996:Survival Rate
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D017273:Goserelin; D005485:Flutamide; D017430:Prostate-Specific Antigen; D002064:Buserelin